Navigation Links
NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology
Date:11/28/2007

HUBBARD, Ohio, Nov. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company announces that the company has submitted international patent applications for BioNanoChannel(TM) and Hydrogen Bioreactor technology protection for China, India, Brazil, and the EU (European Union). These filings are necessary prior to the anticipated global roll-out of the company's BioNanoChannel(TM) rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix's ongoing Hydrogen Bioreactor development.

Chris Novak, NanoLogix Director of IP stated: "The strength and improved focus of the new foreign cases arose from significant improvements to the originally filed provisional patent applications. We at NanoLogix are very excited about the potential for enhancing the patent protection for these new technologies."

According to Bret Barnhizer, NanoLogix President and CEO, "This is a step forward for the company in its plans for technological and business development and sets the stage for one of our corporate goals of pursuing licensing opportunities for use of our products internationally. These applications aid us by ensuring that NanoLogix strengthens their control over the intellectual property rights to the technology."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and 36 Patents Pending for bioreactor-based Hydrogen Production, revolutionary rapid medical testing technologies, potential treatments for sepsis and cancer (via apoptosis), and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alvarado Hospital Files Countersuit Against Blue Shield
2. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
3. Pharsight Files Application for Nasdaq Capital Market Listing
4. Gentiva(R) Health Services Files Universal Shelf Registration Statement
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. CIGNA Behavioral Health Offers Members Online Provider Profiles
7. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
8. RxElite Files Registration Statement with Securities and Exchange Commission
9. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
10. Mach One Corporation Files its Form SB-2 with the SEC
11. CryoCath files patent infringement lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: